Lineage Cell Therapeutics, Inc.
LCTXNYSEHealthcare · Biological Products, (No Diagnostic Substances) · CA · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $14.6M | $9.5M | $8.9M | $14.7M | $4.3M | $1.8M |
| Operating income | −$36.6M | −$21.5M | −$24.7M | −$6.4M | −$7.0M | −$7.4M |
| Net income | −$63.5M | −$18.6M | −$21.5M | −$7.1M | −$1.4M | −$8.4M |
| Total assets | $112.6M | $113.2M | $101.0M | $123.7M | $174.5M | $107.9M |
| Total liabilities | $69.2M | $36.2M | $39.0M | $51.7M | $83.6M | $12.8M |
| Equity | $44.5M | $78.4M | $63.4M | $73.3M | $92.2M | $96.2M |
| EPS (diluted) | $-0.28 | $-0.09 | $-0.12 | $-0.04 | $-0.01 | $-0.06 |
| Shares out. | 228.4M | 188.5M | 170.1M | 169.7M | 161.6M | 149.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −251.6%
- Net margin
- −436.5%
- Return on equity
- −142.6%
- Return on assets
- −56.4%
- Return on capital (ROCE)
- −36.2%
- Liabilities / assets
- 61.5%
- Debt / equity
- 1.55×
- Book value / share
- $0.20
- Revenue growth (YoY)
- 53.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -12.25distress
- Accruals / assets
- −39.6%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Broadwood Partners, L.P.Activist (13D)Nov 14, 2025
- Chernett JoreyPassive (13G)Sep 26, 2025
- Blackrock, Inc.Passive (13G)Jul 17, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 25.9M | 16.8 | +1.3% |
| Apr 30, 2026 | 25.6M | 21.7 | +1.1% |
| Apr 15, 2026 | 25.3M | 24.7 | -0.7% |
| Mar 31, 2026 | 25.5M | 22.3 | +0.0% |
| Mar 13, 2026 | 25.5M | 18.4 | +1.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 12, 2026
- Other material eventMar 11, 2026
- Results of operationsMar 5, 2026
- Other material eventNov 28, 2025
- Other material eventNov 24, 2025
- Other material eventNov 12, 2025
- Results of operationsNov 6, 2025
- Regulation FD disclosure · Other material eventAug 26, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Corporate family
Spin-offs from Lineage Cell Therapeutics, Inc. (2)
- Serina Therapeutics, Inc.SERcompletedNov 28, 2018details
- Insight Molecular Diagnostics Inc.IMDXcompletedDec 31, 2015details
From the spin-off filings we track. Follow a company to walk its own history.